The year of the biotech bull was undoubtedly 2014. Nature Biotechnology has completed a thorough roundup of the runaway successes — and some losers — of the year, in a paper published this week. It’s got a plethora of valuable charts.
Top-grossing biopharmaceuticals
Monoclonal antibody Humira stole the show with $12.5 billion in sales worldwide — half of that hailing from the U.S.
Esperion Sets Its Sights on New Areas While Maintaining Commitment to Cardiovascular Health
In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases
Top IPOs
It seemed as though every other day we had a fresh IPO on our hands. Here are the top 10, in terms of dollars raised:
Top Revenue Gainers & Losers
The year wasn’t quite so fantastic for all biotech players. Arena Pharmaceuticals, for instance, didn’t have the runaway success with its anti-obesity drug Belviq – instead, quite the opposite:
RCM Outsourcing: Balancing Human Expertise & Smart Technology
Greenway Health blends smart technology with human expertise to elevate revenue cycle.
Top Follow-on Offerings
Companies like Receptos and Agios Pharmaceuticals were able to close meaty follow-on rounds, growing their stock value and, in turn, their cash on hand.